Fol. Biol. 2003, 49, 95-99
https://doi.org/10.14712/fb2003049030095
Prospects for Immunotherapy of MHC Class I-Deficient Tumours
References
1. , I., Collado, A., Garrido, F. (1997) Altered MHC class I antigens in tumors. Int. J. Clin. Lab. Res. 27, 95-102.
<https://doi.org/10.1007/BF02912442>
2. , J., Zhang, Q.-J., Gabathuler, R., Reid, G., Chen, S. S., Jefferies, W. A. (2000) TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat. Biotechnol. 18, 515-520.
<https://doi.org/10.1038/75373>
3. , F. R., Stevens, M. H., Griffin, D. B., Thomas, J. A., Bodmer, J. G. (1987) Interferon gamma regulates HLA-D expression on solid tumors in vivo. Eur. J. Cancer Clin. Oncol. 23, 101-106.
<https://doi.org/10.1016/0277-5379(87)90426-3>
4. , U., Klamp, T., Groot, M., Howard, J. C. (1997) Cellular responses to interferon γ. Annu. Rev. Immunol. 15, 749-795.
<https://doi.org/10.1146/annurev.immunol.15.1.749>
5. , J. (2002) Animal models for development of therapeutic HPV16 vaccines (Review). Int. J. Oncol. 20, 207-212.
6. , J., Šímová, J., Hájková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková, E., Vonka, V. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV16. Int. J. Oncol. 14, 593-597.
7. , J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Vonka, V. (2003) Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21, 891-896.
<https://doi.org/10.1016/S0264-410X(02)00537-6>
8. , M., Chang, C.-C., Ferrone, S. (2002) HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20, A40-A45.
<https://doi.org/10.1016/S0264-410X(02)00386-9>
9. , C., de Backer, O., Faraoni, I., Lurquin, C., Brasseur, F., Boon, T. (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. USA 93, 7149-7159.
<https://doi.org/10.1073/pnas.93.14.7149>
10. , M., Samoto, K., Kabos, P., Acosta, F. L., Gutierrez, M. A. R., Black, K. L., Yu, J. S. (2002) Treatment of intracranial glioma with in situ interferongamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther. 9, 925-934.
<https://doi.org/10.1038/sj.cgt.7700516>
11. , C. F., Noessner, E., Weiss, E. H., Schendel, D. J. (2002) Retaliation against tumour cells showing aberrant HLA expression using lymphokine activated killer-derived T cells. Cancer Res. 62, 480-487.
12. , S. V., Ehrlich, R. (2001) IFN-γ affects both the stability and the intracellular transport of class I MHC complexes. J. Interferon Cytokine Res. 21, 199-208.
<https://doi.org/10.1089/107999001750169790>
13. , K., Yang, Y. (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr. Opin. Immunol. 11, 76-81.
<https://doi.org/10.1016/S0952-7915(99)80014-4>
14. , N., Tiwari, N., Momburg, F., Hämmerling, G. J. (2003) A major role for tapasin as a stabilizer of the TAP peptide transporter and consequences for MHC class I expression. Eur. J. Immunol. 33, 264-273.
<https://doi.org/10.1002/immu.200390029>
15. , F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., Stan, P. L. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95.
<https://doi.org/10.1016/S0167-5699(96)10075-X>
16. , D. J., Marincola, F. M., Ferrone, S. (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5, 178-186.
<https://doi.org/10.1016/S1357-4310(99)01451-3>
17. , A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., Levitsky, H. (1994) Role of bone marrowderived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-963.
<https://doi.org/10.1126/science.7513904>
18. , M., Murphy, K. R., Rakhmilevich, A. L., Neal, Z. C., Xiang, R., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. (2001) The level of MHC class expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res. 61, 1500-1507.
19. , M., Bubeník, J., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyšková, R. (2001) Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep. 8, 1371-1374.
20. , M., Bubeník, J., Mikyšková, R., Vonka, V., Šmahel, M., Žák, R., Šímová, J., Bieblová, J., Mendoza, L., Jandlová, T. (2002) Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class Itumours of HPV16 origin. Int. J. Oncol. 20, 643-646.
21. , M., Bubeník, J., Mikyšková, R., Mendoza, L., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Pajtasz-Piasecká, E. (2003) Chemoimmunotherapy in mice carrying HPV16-associated MHC class I+ and class Itumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22, 691-695.
22. , E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jäger, D., Oesch, F., Knuth, A. (1997) Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71, 142-147.
<https://doi.org/10.1002/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0>
23. , S., Tagawa, Y.-I., Shibata, S., Nanno, M. (2002) Inhibition of B16 melanoma experimental metastasis by interferon γ through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology 105, 92-100.
<https://doi.org/10.1046/j.0019-2805.2001.01342.x>
24. , M., Jung, D., Hilmes, C., Knuth, A., Jaeger, E., Huber, C., Seliger, B. (1999) Induction of immunogenicity of a human renal cell carcinoma cell line by TAP1-gene transfer. Int. J. Cancer 81, 125-133.
<https://doi.org/10.1002/(SICI)1097-0215(19990331)81:1<125::AID-IJC21>3.0.CO;2-2>
25. , D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., Schreiber, R. D. (1998) Demonstration of an interferon γ-dependent tumour surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556-75561.
<https://doi.org/10.1073/pnas.95.13.7556>
26. , H. T., Restifo, N. P. (2002) Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat. Immunol. 3, 999-1005.
<https://doi.org/10.1038/ni1102-999>
27. , H. I., Lazenby, A., Hayashi, R. J., Pardoll, D. M. (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179, 1215-1224.
<https://doi.org/10.1084/jem.179.4.1215>
28. , Y., Yamagishi, N., Koshita, Y., Fujiwara, H., Sato, Y., Fujii, S., Takahashi, M., Sato, T., Kato, J., Yamagishi, H., Niitsu, Y. (2001) Administration of subtumor regression dosage of TNF-α to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule. Gene Ther. 8, 499-507.
<https://doi.org/10.1038/sj.gt.3301429>
29. , R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Šímová, J., Jandlová, T. (2001) Local cytokine treatment of HPV 16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis 18, 581-587.
<https://doi.org/10.1023/A:1011987206008>
30. , Bieblová, R., Šímová, J., Indrová, M., Jandlová, T., Vonka, V., Šmahel, M., Bubeník, J., Mendoza, L. (2003) Local IFN-γ therapy of HPV16-associated tumours. Folia Biol. (Praha) 49, 26-32.
31. , P., Mouillot, G., Rousseau, P., Marcon, C., Dausset, J., Carosella, E. D. (2003) HLA-G gene repression is reversed by demethylation. Proc. Natl. Acad. Sci. USA 100, 1191-1196.
<https://doi.org/10.1073/pnas.0337539100>
32. , P., Rossi, I., De Giovanni, C., Landuzzi, L., Nicoletti, G., Stoppacciaro, A., Parenza, M., Colombo, M. P., Lollini, P.-L. (1998) Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 58, 1225-1230.
33. , M., Gagnon, J., Momparler, R. L. (2003) Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int. J. Cancer 103, 177-184.
<https://doi.org/10.1002/ijc.10789>
34. , N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yanelli, J. R., Rosenberg, S. A. (1996) Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88, 100-108.
<https://doi.org/10.1093/jnci/88.2.100>
35. , B., Harders, C., Lohmann, S., Momburg, F., Urlinger, S., Tampe, R., Huber, C. (1998) Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur. J. Immunol. 28, 122-133.
<https://doi.org/10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F>
36. , B., Maeurer, M. J., Ferrone, S. (2000) Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21, 455-464.
<https://doi.org/10.1016/S0167-5699(00)01692-3>
37. , M. J., Calvin, R. B., Schneeberger, E. E., Russel, P. S. (1985) Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by γ interferon. J. Exp. Med. 162, 1645-1664.
<https://doi.org/10.1084/jem.162.5.1645>
38. , M., Sobotková, E., Bubeník, J., Šímová, J., Žák, R., Ludvíková, V., Hájková, R., Kovařík, J., Jelínek, F. (2001) Metastatic MHC class 1 negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84, 374-380.
<https://doi.org/10.1054/bjoc.2000.1615>
39. , B. D. (2000) HLA class I expression on human cancer cells. Implications for effective immunotherapy. Human Immunol. 61, 158-165.
<https://doi.org/10.1016/S0198-8859(99)00150-0>
40. , R. J., Zeff, R. A. (1993) Regulated expression of the major histocompatibility complex class I genes. Proc. Soc. Exp. Biol. Med. 203, 405-417.
<https://doi.org/10.3181/00379727-203-43616A>
41. , J. (2003) Novel interferons. Nat. Immunol. 4, 8-9.
<https://doi.org/10.1038/ni0103-8>
42. , J., Salgaller, M., Samid, D., Johnson, B., Herlyn, M., Lassam, N., Treisman, J., Rosenberg, S. A. (1994) Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 54, 1766-1771.
43. , P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., Ferrant, A. (2000) Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18, 956-962.
<https://doi.org/10.1200/JCO.2000.18.5.956>
44. , S. J., Lee, J. C., Kang, J. O., Lee, S. G., Heo, D. S. (2001) Anti-tumor effect associated with down-regulation of MHC class I antigen after co-transfection of GM-CSF and IFNγ genes in CT26 tumor cells. Anticancer Res. 21, 4031-4040.
